MLTX
MoonLake Immunotherapeutics
1W: -5.0%
1M: -10.5%
3M: +16.6%
YTD: +36.1%
1Y: -59.2%
3Y: -19.9%
5Y: +55.0%
$16.27
-0.41 (-2.46%)
After Hours: $16.35 (+0.08, +0.49%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$11.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.2B
52W Range5.95-62.75
Volume626,426
Avg Volume1,986,152
Beta1.24
Dividend—
Analyst Ratings
Company Info
CEOJorge Santos da Silva
Employees100
SectorHealthcare
IndustryBiotechnology
IPO Date2020-10-20
Websitemoonlaketx.com
Dorfstrasse 29
Zug 6300
CH
Zug 6300
CH
41 415108022
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Latest News
MoonLake upgraded at Rothschild & Co Redburn citing potential FDA nod for lead drug
Caitong International Asset Management Co. Ltd Increases Holdings in MoonLake Immunotherapeutics $MLTX
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Analysts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bodenstedt Matthias | A-Award | 354,296 | — | 2026-01-07 |
| Santos da Silva Jorg | A-Award | 520,342 | $11.29 | 2026-01-07 |
| Reich Kristian | A-Award | 520,342 | $11.29 | 2026-01-07 |
| Bodenstedt Matthias | C-Conversion | 294,473 | — | 2025-12-19 |
| Bodenstedt Matthias | D-Return | 294,473 | — | 2025-12-19 |